Pharmaceutical

Rigosertib sodium by Traws Pharma for Epidermolysis Bullosa: Likelihood of Approval

Rigosertib sodium is under clinical development by Traws Pharma and currently in Phase II for Epidermolysis Bullosa.

Apr 19, 2024 - 00:00
Rigosertib sodium is under clinical development by Traws Pharma and currently in Phase II for Epidermolysis Bullosa.
Read the original article

Tags:

Previous Article

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Solid Tumor: Likelihood ...

Next Article

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Hodgkin Lymphoma (B-Cell...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA advisory panel backs Pfizer’s RSV vaccine, but expresses some safety concerns

FDA advisory panel backs Pfizer’s RSV vaccine, but expr...

May 19, 2023

SK Bioscience gains UK authorisation for SKYCovion Covid-19 vaccine

SK Bioscience gains UK authorisation for SKYCovion Covi...

May 30, 2023

Signal: Wegovy highlights UK’s complex relationship with private sector

Signal: Wegovy highlights UK’s complex relationship wit...

Nov 20, 2023